Skip to content

APIOC Sphere and APIOC Astigmatism

7 Day Trial of APIOC Sphere and APIOC Astigmatism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04806802
Enrollment
50
Registered
2021-03-19
Start date
2021-03-18
Completion date
2021-10-31
Last updated
2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Hyperopia, Myopia

Brief summary

Vision and comfort, both objective and subjective, will be assessed for single vision contact lens wearers for either the APIOC™ Sphere or the APIOC™ Astigmatism contact lenses.

Interventions

DEVICEAPIOC Sphere and APIOC Astigmatism

Single Vision Contact Lenses

Sponsors

Lentechs, LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

1. The subject must provide written informed consent. 2. The subject must appear willing and able to adhere to the instructions set forth in this protocol. 3. At least 18 years of age and no more than 35 years of age. 4. ≤ 4.00 D (diopters) of corneal astigmatism. 5. ≤ 2.50 D of refractive astigmatism. 6. Refractive error range +4.00 DS to -6.00 DS (diopters sphere) 7. Flat and steep keratometry readings within 40 to 48 D. 8. Clear, healthy corneas with no irregular astigmatism. 9. Normal, healthy conjunctiva in both eyes. 10. Free of active ocular disease. Refractive error is permitted. 11. Be a current or former (within the last 12 months) contact lens wearer. 12. Best-corrected near and distance visual acuity better than or equal to 20/25.

Exclusion criteria

1. Irregular corneal astigmatism. 2. Presbyopia 3. Corneal scarring unless off line-of-site and well healed. 4. Pinguecula, pterygium, or other conjunctival thickness abnormalities that would interfere with soft contact lens wear. 5. Recent use of any ocular pharmaceutical treatments, including daily artificial tears, in the two weeks prior to the examination. Use of artificial tears less than 3 drops per week is permitted. 6. Systemic disease that would interfere with contact lens wear. 7. Currently pregnant or lactating (by self-report). 8. History of strabismus or eye movement disorder, including exophoria at near that is 4 D or greater than at far, and a receded near point of convergence break that is 6 cm or greater. 9. Active allergies that may inhibit contact lens wear. 10. Upper eyelid margin at or above the superior limbus. 11. History of ocular or lid surgery. 12. Immediate family members or significant others of doctors or staff at the clinical site.

Design outcomes

Primary

MeasureTime frameDescription
Visual AcuityDay 7High and Low Contrast LogMAR, Distance
Subjective Vision QualityDay 7Visual analogue scale
ComfortDay 7Visual analogue scale

Secondary

MeasureTime frameDescription
Subjective comfortDay 7Compared to habitual lenses
Subjective visionDay 7Compared to habitual lenses

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026